Details of Disease

General Information of Disease (ID: DIS8R9VO)

• Disease Name: Rectal adenocarcinoma
• Synonyms: read; rectum adenocarcinoma; rectal adenocarcinoma; adenocarcinoma of the rectum; adenocarcinoma of rectum; adenocarcinoma - rectum
• Disease Class: 2B92: Rectum cancer
• Definition: An adenocarcinoma arising from the rectum. It is more frequently seen in populations with a Western type diet and in patients with a history of chronic inflammatory bowel disease. Signs and symptoms include intestinal bleeding, anemia, and change in bowel habits. According to the degree of cellular differentiation, rectal adenocarcinomas are divided into well, moderately, and poorly differentiated. Histologic variants include mucinous adenocarcinoma, signet ring cell carcinoma, medullary carcinoma, serrated adenocarcinoma, cribriform comedo-type adenocarcinoma, and micropapillary adenocarcinoma.
• Disease Hierarchy:
  DIS3IHTY: Adenocarcinoma
  DISPQOUB: Colorectal adenocarcinoma
  DIS8FRR7: Rectal carcinoma
  DIS8R9VO: Rectal adenocarcinoma
• ICD Code:
  ICD-11: ICD-11: 2B92
  ICD-10: ICD-10: C20
  ICD-9: ICD-9: 154
  Expand ICD-11: '2B92
  Expand ICD-10: 'C20
  Expand ICD-9: 154
• Disease Identifiers:
  MONDO ID: MONDO_0002169
  UMLS CUI: C0149978
  MedGen ID: 56214
  SNOMED CT ID: 254582000

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 9 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Bevacizumab	DMSD1UN	Approved	Monoclonal antibody	[1]
Capecitabine	DMTS85L	Approved	Small molecular drug	[2]
Fluorouracil	DMUM7HZ	Approved	Small molecular drug	[3]
Gefitinib	DM15F0X	Approved	Small molecular drug	[4]
Irinotecan	DMP6SC2	Approved	Small molecular drug	[5]
Leucovorin	DMUAZWG	Approved	Small molecular drug	[6]
Levoleucovorin	DMH5LME	Approved	Small molecular drug	[7]
Oxaliplatin	DMQNWRD	Approved	Small molecular drug	[8]
Raltitrexed	DMT9K8G	Approved	Small molecular drug	[9]

This Disease is Treated as An Indication in 2 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
MK-2206	DMT1OZ6	Phase 2	Small molecular drug	[10]
E7046	DMFVT43	Phase 1	NA	[11]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 3 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
SCG3	TTY5R9H	Limited	Biomarker	[12]
ADCY1	TTV1ZSQ	Strong	Biomarker	[13]
PPME1	TTXQ54R	Strong	Altered Expression	[14]

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC45A3	DTGEFXH	Strong	Biomarker	[15]

This Disease Is Related to 9 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
HOMER2	OT4JGKJF	Limited	Altered Expression	[12]
RAB5C	OTQE5QQ2	Limited	Biomarker	[16]
RAPH1	OTMQXW7S	Limited	Biomarker	[17]
RUNDC3A	OTHP1DRS	Limited	Biomarker	[12]
CCNB2	OTIEXTDK	Strong	Biomarker	[18]
GNGT1	OTEPUP1U	Strong	Altered Expression	[19]
MAGEB6	OTOTV1FU	Strong	Biomarker	[20]
PEG10	OTWD2278	Strong	Altered Expression	[13]
RAB27B	OTPF9D0K	Strong	Altered Expression	[13]

References

• [1] Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as?preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term?results. BMC Cancer. 2020 Nov 27;20(1):1164.
• [2] Capecitabine FDA Label
• [3] Fluorouracil FDA Label
• [4] Gefitinib FDA Label
• [5] Irinotecan FDA Label
• [6] Leucovorin FDA Label
• [7] Levoleucovorin FDA Label
• [8] Oxaliplatin FDA Label
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7403).
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7945).
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] Identification of two novel biomarkers of rectal carcinoma progression and prognosis via co-expression network analysis.Oncotarget. 2017 Jun 27;8(41):69594-69609. doi: 10.18632/oncotarget.18646. eCollection 2017 Sep 19.
• [13] Identification of the potential biomarkers for the metastasis of rectal adenocarcinoma.APMIS. 2017 Feb;125(2):93-100. doi: 10.1111/apm.12633. Epub 2016 Dec 28.
• [14] Protein phosphatase methylesterase-1 (PME-1) expression predicts a favorable clinical outcome in colorectal cancer.Cancer Med. 2015 Dec;4(12):1798-808. doi: 10.1002/cam4.541. Epub 2015 Sep 17.
• [15] Differentiating rectal carcinoma by an immunohistological analysis of carcinomas of pelvic organs based on the NCBI Literature Survey and the Human Protein Atlas database.Surg Today. 2012 Jun;42(6):515-25. doi: 10.1007/s00595-012-0167-z. Epub 2012 Mar 23.
• [16] Rab5C enhances resistance to ionizing radiation in rectal cancer.J Mol Med (Berl). 2019 Jun;97(6):855-869. doi: 10.1007/s00109-019-01760-6. Epub 2019 Apr 9.
• [17] Lamellipodin-Deficient Mice: A Model of Rectal Carcinoma.PLoS One. 2016 Apr 5;11(4):e0152940. doi: 10.1371/journal.pone.0152940. eCollection 2016.
• [18] Screening key lncRNAs for human rectal adenocarcinoma based on lncRNA-mRNA functional synergistic network.Cancer Med. 2019 Jul;8(8):3875-3891. doi: 10.1002/cam4.2236. Epub 2019 May 22.
• [19] Comprehensive Analysis of Core Genes and Potential Mechanisms in Rectal Cancer.J Comput Biol. 2019 Nov;26(11):1262-1277. doi: 10.1089/cmb.2019.0073. Epub 2019 Jun 18.
• [20] Association of Plane of Total Mesorectal Excision With Prognosis of Rectal Cancer: Secondary Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial.JAMA Surg. 2018 Aug 1;153(8):e181607. doi: 10.1001/jamasurg.2018.1607. Epub 2018 Aug 15.